| P2093 | author name string | Ronald E See | |
| | Matthew W Feltenstein | |
| | Phong H Do | |
| P2860 | cites work | Nicotine receptor partial agonists for smoking cessation | Q24242786 |
| | Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist | Q28141108 |
| | From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol | Q28211980 |
| | Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000-2001 | Q28241400 |
| | A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior | Q28373340 |
| | Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes | Q28375923 |
| | Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) | Q28377445 |
| | The reinstatement model of drug relapse: history, methodology and major findings | Q29616241 |
| | Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking | Q30501299 |
| | Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists | Q31409124 |
| | Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats | Q33748306 |
| | Dopamine receptor partial agonists could address the duality of cocaine craving | Q33818914 |
| | The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 |
| | Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride | Q33959951 |
| | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 |
| | The psychology and neurobiology of addiction: an incentive-sensitization view | Q34043729 |
| | Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans | Q34083204 |
| | Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding | Q34154263 |
| | Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats | Q34222033 |
| | Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain | Q34326136 |
| | Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. | Q34375654 |
| | Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission | Q34400155 |
| | Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats | Q34413520 |
| | Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors | Q34414507 |
| | Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain | Q34429958 |
| | Cocaine dependence: a disease of the brain's reward centers | Q34453329 |
| | Aripiprazole: A New Atypical Antipsychotic Drug | Q34533055 |
| | Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse | Q34542612 |
| | Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra | Q48088371 |
| | In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain | Q48292762 |
| | Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. | Q48307357 |
| | Neuroadaptations involved in amphetamine and cocaine addiction | Q48405820 |
| | Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats | Q48432762 |
| | Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. | Q48521950 |
| | Cocaine-induced cocaine craving | Q48933520 |
| | Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area | Q48940484 |
| | Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. | Q51677156 |
| | Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. | Q51899284 |
| | Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. | Q55044398 |
| | Intrinsic activity: partial agonists and partial antagonists | Q72695769 |
| | Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys | Q73434461 |
| | Aripiprazole | Q78382372 |
| | A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence | Q79485956 |
| | Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability | Q34548876 |
| | The potential of dopamine agonists in drug addiction | Q34581491 |
| | The role of dorsal vs ventral striatal pathways in cocaine-seeking behavior after prolonged abstinence in rats | Q34641435 |
| | Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development | Q34954205 |
| | Different neural substrates mediate cocaine seeking after abstinence versus extinction training: a critical role for the dorsolateral caudate-putamen | Q35141659 |
| | Mechanism of new antipsychotic medications: occupancy is not just antagonism | Q35558773 |
| | Dopamine partial agonists: a new class of antipsychotic | Q35688765 |
| | Combating opiate dependence: a comparison among the available pharmacological options | Q35753371 |
| | Prevention of relapse to addiction: information for the practitioner. | Q35775105 |
| | Medication development for addictive disorders: the state of the science | Q36213569 |
| | Varenicline for smoking cessation | Q36730647 |
| | The neurocircuitry of addiction: an overview | Q36741890 |
| | Controversies in translational research: drug self-administration | Q37087986 |
| | Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). | Q37351968 |
| | Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration | Q37353914 |
| | Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. | Q37436084 |
| | An analysis of drug-seeking behavior in animals | Q40318712 |
| | A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine | Q40342675 |
| | Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans | Q40409535 |
| | Changing patterns of "drug abuse" in the United States: connecting findings from macro- and microepidemiologic studies | Q40639353 |
| | Cue reactivity and cue reactivity interventions in drug dependence | Q40805426 |
| | Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats | Q40912893 |
| | Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. | Q42659868 |
| | Aripiprazole in schizophrenia with cocaine dependence: a pilot study | Q42662209 |
| | Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. | Q43847484 |
| | Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 |
| | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. | Q44167467 |
| | Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference | Q44289384 |
| | Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys. | Q44317528 |
| | Cocaine-Seeking Behavior in Response to Drug-Associated Stimuli in Rats: Involvement of D3 and D2 Dopamine Receptors | Q44407095 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia | Q44649979 |
| | Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. | Q44735526 |
| | Differential involvement of orbitofrontal cortex subregions in conditioned cue-induced and cocaine-primed reinstatement of cocaine seeking in rats. | Q44989791 |
| | A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study | Q45188329 |
| | Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers | Q45882572 |
| | Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats | Q46057186 |
| | Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia | Q46416379 |
| | High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study | Q46493258 |
| | Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats | Q46591374 |
| | Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex | Q46603510 |
| | The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine-induced locomotor stimulation in mice | Q46688517 |
| | Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models | Q46829192 |
| | The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance | Q46906540 |
| | Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size | Q47402091 |
| P433 | issue | 3 | |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 401-411 | |
| P577 | publication date | 2009-09-25 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse | |
| P478 | volume | 207 | |